CVAC - CureVac: No Momentum In Sight
2024-03-08 10:11:10 ET
Summary
- CureVac faces challenges as a German court invalidates one of their key mRNA technology patents, raising concerns about their ability to compete in the mRNA space.
- The invalidated patent relates to an invention that many argue was not a genuine "invention" as the concepts and technologies were already well-known in the scientific community.
- CureVac's future prospects rely heavily on their partnerships, such as their joint effort with GSK for influenza and COVID vaccines, and their RNA Printer technology for point-of-care production of RNA therapeutics.
...
CureVac: No Momentum In Sight